Gilead Sciences (United States)
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Derived from Wikipedia licensed CC-BY-SA.
Open Access statistics for Gilead Sciences (United States), United States, covering academic research published from 2000 to 2024. Read More.
Open Access Percentage
54%
Total
Publications
5.6K
Total Open
Publications
3K
Total
Citations
258K
Open Access
Percentage
54%
Total
Publications
5.6K
Total Open
Publications
3K
Total
Citations
258K
Breakdown
Publisher Open
18%
Both
25%
Other Platform Open
10%
Closed
47%
Percentage of Open Access over time
Publisher Open
Both
Other Platform Open
Closed
Volume of Open Access over time
Open
Closed
Publisher Open
OA Journal 43%
1K
Hybrid 23%
538
No Guarantees 34%
808
Other Platform Open
Domain 74%
1.5K
Other Internet 19%
383
Institution 18%
358
Preprint 4%
85
Public 3%
55
Other Platform Locations
Name | Platform Type | Publications |
|---|---|---|
PubMed Central | Domain | 1.5K |
DOI | Other Internet | 374 |
Europe PMC | Domain | 71 |
Figshare | Public | 51 |
bioRxiv | Preprint | 48 |
Royal Netherlands Academy of Arts and Sciences | Institution | 35 |
Le Centre pour la Communication Scientifique Directe - HAL - Diderot | Institution | 32 |
University of Modena and Reggio Emilia | Institution | 25 |
Unknown Repository | Other Internet | 21 |
Université Libre de Bruxelles | Institution | 18 |